These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 29636906)

  • 1. Hazard and risk assessment strategies for nanoparticle exposures: how far have we come in the past 10 years?
    Warheit DB
    F1000Res; 2018; 7():376. PubMed ID: 29636906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk assessment strategies for nanoscale and fine-sized titanium dioxide particles: Recognizing hazard and exposure issues.
    Warheit DB; Donner EM
    Food Chem Toxicol; 2015 Nov; 85():138-47. PubMed ID: 26362081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How to measure hazards/risks following exposures to nanoscale or pigment-grade titanium dioxide particles.
    Warheit DB
    Toxicol Lett; 2013 Jul; 220(2):193-204. PubMed ID: 23603385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health effects related to nanoparticle exposures: environmental, health and safety considerations for assessing hazards and risks.
    Warheit DB; Sayes CM; Reed KL; Swain KA
    Pharmacol Ther; 2008 Oct; 120(1):35-42. PubMed ID: 18703086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A role for nanoparticle surface reactivity in facilitating pulmonary toxicity and development of a base set of hazard assays as a component of nanoparticle risk management.
    Warheit DB; Reed KL; Sayes CM
    Inhal Toxicol; 2009 Jul; 21 Suppl 1():61-7. PubMed ID: 19558235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing toxicity of fine and nanoparticles: comparing in vitro measurements to in vivo pulmonary toxicity profiles.
    Sayes CM; Reed KL; Warheit DB
    Toxicol Sci; 2007 May; 97(1):163-80. PubMed ID: 17301066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Naturally occurring asbestos: a recurring public policy challenge.
    Lee RJ; Strohmeier BR; Bunker KL; Van Orden DR
    J Hazard Mater; 2008 May; 153(1-2):1-21. PubMed ID: 18180100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanotechnology safety concerns revisited.
    Stern ST; McNeil SE
    Toxicol Sci; 2008 Jan; 101(1):4-21. PubMed ID: 17602205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rationale of genotoxicity testing of nanomaterials: regulatory requirements and appropriateness of available OECD test guidelines.
    Warheit DB; Donner EM
    Nanotoxicology; 2010 Dec; 4():409-13. PubMed ID: 20925448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The hierarchy of environmental health and safety practices in the U.S. nanotechnology workplace.
    Engeman CD; Baumgartner L; Carr BM; Fish AM; Meyerhofer JD; Satterfield TA; Holden PA; Harthorn BH
    J Occup Environ Hyg; 2013; 10(9):487-95. PubMed ID: 23927041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proceedings of the Second Workshop on Theory meets Industry (Erwin-Schrödinger-Institute (ESI), Vienna, Austria, 12-14 June 2007).
    Hafner J
    J Phys Condens Matter; 2008 Feb; 20(6):060301. PubMed ID: 21693862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Challenges in assessing nanomaterial toxicology: a personal perspective.
    Geraci CL; Castranova V
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2010; 2(6):569-77. PubMed ID: 20799267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Next generation testing strategy for assessment of genomic damage: A conceptual framework and considerations.
    Dearfield KL; Gollapudi BB; Bemis JC; Benz RD; Douglas GR; Elespuru RK; Johnson GE; Kirkland DJ; LeBaron MJ; Li AP; Marchetti F; Pottenger LH; Rorije E; Tanir JY; Thybaud V; van Benthem J; Yauk CL; Zeiger E; Luijten M
    Environ Mol Mutagen; 2017 Jun; 58(5):264-283. PubMed ID: 27650663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The carcinogenic potential of nanomaterials, their release from products and options for regulating them.
    Becker H; Herzberg F; Schulte A; Kolossa-Gehring M
    Int J Hyg Environ Health; 2011 Jun; 214(3):231-8. PubMed ID: 21168363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Debunking some misconceptions about nanotoxicology.
    Warheit DB
    Nano Lett; 2010 Dec; 10(12):4777-82. PubMed ID: 21033694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanoparticles: a review of particle toxicology following inhalation exposure.
    Bakand S; Hayes A; Dechsakulthorn F
    Inhal Toxicol; 2012; 24(2):125-35. PubMed ID: 22260506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a base set of toxicity tests using ultrafine TiO2 particles as a component of nanoparticle risk management.
    Warheit DB; Hoke RA; Finlay C; Donner EM; Reed KL; Sayes CM
    Toxicol Lett; 2007 Jul; 171(3):99-110. PubMed ID: 17566673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The implementation of medical monitoring programs following potentially hazardous exposures: a medico-legal perspective.
    Vearrier D; Greenberg MI
    Clin Toxicol (Phila); 2017 Nov; 55(9):956-969. PubMed ID: 28644057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Linking Exposures of Particles Released From Nano-Enabled Products to Toxicology: An Integrated Methodology for Particle Sampling, Extraction, Dispersion, and Dosing.
    Pal AK; Watson CY; Pirela SV; Singh D; Chalbot MC; Kavouras I; Demokritou P
    Toxicol Sci; 2015 Aug; 146(2):321-33. PubMed ID: 25997654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.